Edwards Lifesciences Files 8-K on Financial Results & Condition
Ticker: EW · Form: 8-K · Filed: Feb 6, 2024 · CIK: 1099800
| Field | Detail |
|---|---|
| Company | Edwards Lifesciences Corp (EW) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: earnings, financial-results, 8-K, corporate-filing
TL;DR
**Edwards Lifesciences just dropped an 8-K on financial results, so expect market reaction.**
AI Summary
Edwards Lifesciences Corporation filed an 8-K on February 6, 2024, to report its financial results and condition, as well as to include related financial statements and exhibits. This filing, under Items 2.02 and 9.01, indicates the company is providing an update on its performance. For investors, this matters because it offers a timely look into the company's financial health, which can influence stock price and future investment decisions.
Why It Matters
This filing provides investors with crucial, up-to-date financial information, allowing them to assess the company's performance and make informed investment decisions.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial results, which is standard for public companies and does not inherently indicate high risk.
Analyst Insight
Investors should review the full financial statements and exhibits referenced in this 8-K to understand the detailed results of operations and financial condition before making any investment decisions.
Key Numbers
- 001-15525 — SEC File Number (identifies the company's registration with the SEC)
- 949-250-2500 — Business Phone Number (contact information for the company)
- 16 — Public Document Count (number of documents included in the filing)
Key Players & Entities
- Edwards Lifesciences Corporation (company) — the registrant filing the 8-K
- February 6, 2024 (date) — date of the earliest event reported and filing date
- New York Stock Exchange (company) — exchange where Edwards Lifesciences' Common Stock is registered
- $1.00 (dollar_amount) — par value per share of Common Stock
Forward-Looking Statements
- Edwards Lifesciences' stock (EW) will experience increased trading volume following the release of its financial results. (EW) — high confidence, target: 2024-02-07
- Analysts will update their price targets and ratings for Edwards Lifesciences based on the financial condition reported. (Edwards Lifesciences Corporation) — medium confidence, target: 2024-02-13
FAQ
What specific items are being reported in this 8-K filing by Edwards Lifesciences Corporation?
Edwards Lifesciences Corporation is reporting under Item 2.02, "Results of Operations and Financial Condition," and Item 9.01, "Financial Statements and Exhibits," as stated in the filing.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is EDWARDS LIFESCIENCES CORPORATION, according to the filing.
On what date was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on February 6, 2024, as indicated by the 'FILED AS OF DATE' and 'Date of Report (Date of earliest event reported)'.
What is the trading symbol for Edwards Lifesciences Corporation's Common Stock?
The trading symbol for Edwards Lifesciences Corporation's Common Stock is EW, as listed under 'Securities registered pursuant to Section 12(b) of the Act'.
Where is Edwards Lifesciences Corporation's principal executive office located?
Edwards Lifesciences Corporation's principal executive office is located at One Edwards Way, Irvine, California 92614, as stated in the business address section of the filing.
Filing Stats: 477 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-02-06 16:23:49
Key Financial Figures
- $1.00 — ich registered Common Stock, par value $1.00 per share EW New York Stock Exchange
Filing Documents
- ew-20240206.htm (8-K) — 33KB
- ex-991q42023.htm (EX-99.1) — 478KB
- ew45percentblacklrga21a.jpg (GRAPHIC) — 625KB
- 0001099800-24-000002.txt ( ) — 1521KB
- ew-20240206.xsd (EX-101.SCH) — 2KB
- ew-20240206_lab.xml (EX-101.LAB) — 24KB
- ew-20240206_pre.xml (EX-101.PRE) — 12KB
- ew-20240206_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 6, 2024, Edwards Lifesciences Corporation, a Delaware corporation ("Edwards"), issued a press release setting forth Edwards' financial results for the fourth quarter of 2023. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated February 6, 2024, reporting Edwards' financial results for the fourth quarter of 2023. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 6, 2024 EDWARDS LIFESCIENCES CORPORATION By: /s/ Scott B. Ullem Scott B. Ullem Chief Financial Officer 3 Exhibit Index Exhibit Number Description 99.1 Press release, dated February 6, 2024 , reporting Edwards' financial results for the fourth quarter of 2023. 4